Nicholas D. James, PhD, MBBS, on Adding Abiraterone to Hormone Therapy in Prostate Cancer: STAMPEDE Trial on Cost-Effectiveness
2020 Genitourinary Cancers Symposium
Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research in London, discusses the health economics of adding abiraterone to first-line, long-term hormone therapy in prostate cancer, and what it means for long-term survival, quality-adjusted survival, and cost-effectiveness (Abstract 204).
The ASCO Post Staff
Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research in London, discusses results from a phase I/II feasibility study that showed the combination of cetuximab, chemoradiation, fluorouracil, and mitomycin yields high bladder cancer control rates with acceptable toxicity and quality of life, meriting further evaluation in a randomized trial (Abstract 491).
The ASCO Post Staff
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, describes a currently recruiting phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab vs nivolumab/ipilimumab for patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk (Abstract TPS767).
The ASCO Post Staff
Julie N. Graff, MD, of Oregon Health & Science University and Knight Cancer Institute, discusses study findings that show pembrolizumab plus enzalutamide after progression on enzalutamide produced clinical activity and can lead to durable responses, with a manageable safety profile. The phase III KEYNOTE-641 trial will test patients who are enzalutamide-naive (Abstract 15).
The ASCO Post Staff
Ziad Bakouny, MD, of Dana-Farber Cancer Institute, discusses the controversial and ill-defined role of cytoreductive nephrectomy in treating patients with metastatic renal cell carcinoma who have received targeted therapies or immune checkpoint inhibitors (Abstract 608).
The ASCO Post Staff
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses study results which showed that, in first-line cisplatin-ineligible patients with metastatic urothelial carcinoma, enfortumab vedotin/pembrolizumab demonstrated activity and durability, with a manageable safety profile (Abstract 441).
